← Back to search

National Institutes of Health · Department of Health and Human Services

Drug Development Infrastructure Supporting the Research Community in Medication Repurposing for Substance Use Disorders

Opening soon

In short: National Institutes of Health expects to make 1 award. Open to many kinds of groups. See who can apply.

Key facts

Deadline
Opens Feb 25, 2027 · due about Jun 1, 2027 Estimate, not confirmed by the funder ?
Award size
Not stated: see the official notice
Total available
$2.5M · about 1 award
Match ?
Not required · Work out your budget and match
Who can apply
State government, County government, Tribal organization, Public college or university, City or town government, Private college or university, Nonprofit with 501(c)(3), Small business, Nonprofit without 501(c)(3), Special district (utility, fire, etc.), Tribal government, School district, Larger business, and others named in the official notice
Where
Anywhere in the U.S., including Tennessee

Opening soon: the funder has announced this grant, but you can't apply yet. Use the time to get ready and check whether it fits.

Before you apply: federal grants require an active SAM.gov registration (Unique Entity ID) and a Grants.gov account. Registration is free but can take weeks, so start now, not when the deadline is close. Get-ready checklist

How this fits you

  • Available in Tennessee (nationwide program)
  • No match required

Tell us who you are to see whether you're eligible.

About this grant

The National Institute on Drug Abuse (NIDA) seeks to advance its mission by supporting a dynamic and adaptable drug-development infrastructure to accelerate medication repurposing and repositioning for substance use disorders (SUDs). The infrastructure will serve academic and biotech investigators by providing coordinated scientific expertise, shared resources, and tailored support across the drug-development continuum. Capabilities may include in silico discovery, target and assay validation, preclinical and translational development, pharmacology, toxicology, clinical protocol development, patient engagement, Target Product Profile development, Freedom-to-Operate and intellectual property strategy, regulatory guidance, and market-access planning. The infrastructure will also engage the research community through outreach, proposal solicitation, and a structured project-selection process, supporting user-led projects across a broad range of SUD indications. The goal is to help promising repurposed and repositioned therapeutics progress toward clinical development and potential market access. Grant authorities that allow the NIDA to forecast this opportunity are as follows: 42 U.S.C. 241 and 284.

Who can apply, from the official notice

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

View on Grants.gov Add dates to my calendar

Ask a partner for a letter

Similar grants open or opening soon

From other funders, about the same kind of work.

More from National Institutes of Health

About the federal program

Drug Use and Addiction Research Programs - Research Centers
Program number 93.DA5 (the federal Assistance Listing number) · U.S. Department of Health and Human Services, National Institutes of Health · Grant, cooperative agreement (a grant with close agency involvement)

How applications are judged

The following considerations will be used in determining projects to be funded: (1) Scientific and technical merit; (2) the feasibility of the research; (3) potential contribution to the national drug use problem; and (4) relevance to NIDA priorities.

Match

None required (federal program listing).

This program on SAM.gov

Something wrong on this page? Tell us
What's wrong?

Source: Federal grants from Grants.gov · the official federal record. Last checked by GrantMe Nov 22, 2026.

Reference numbers: official notice number RFA-DA-28-009 · program number 93.DA5